Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
12 evidence topics · 12 sources
Progression to metastatic castration-resistant disease as the cause of prostate cancer death
Modeled share of U.S. prostate cancer deaths occurring in metastatic castration-resistant states
Estimated U.S. deaths in 2026, all prostate cancer stages
| Measure | Quoted value |
|---|---|
| Estimated deaths from prostate cancer, United States, 2026 | “36,320”View highlighted excerpt for this quote |
U.S. prostate cancer mortality trend, all stages
“Increased incidence also may be contributing to a deceleration in the decline for prostate cancer mortality, from 3.5% per year during the late 1990s and 2000s to 0.6% per year from 2012 through 2023 (Table 8, Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distant-stage five-year relative survival, all metastatic prostate cancer
| SEER measure | Quoted value |
|---|---|
| Distant-stage five-year relative survival | “40.1%” |
Overall survival in metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023
Overall survival in metastatic castration-resistant prostate cancer, Medicare fee-for-service cohort 2014 to 2019
“Overall mortality in the cohort was 54%. Median survival from mCRPC diagnosis was 25.6 months (95% confidence interval [CI] 25.0–26.2 months) (Fig. 3). Median survival from treatment initiation was 23.4 months (95% CI: 22.8–24.1 months)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival in metastatic castration-resistant prostate cancer after metastatic hormone-sensitive disease, U.S. ConcertAI cohort 2020 to 2023
“Median real-world overall survival was 27.2 months from mCRPC diagnosis and 20.8 months from 1L therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Back-to-back ARPI use from mHSPC to mCRPC is common in current clinical practice and survival remains <3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world overall survival across observational studies
Overall survival after an androgen receptor pathway inhibitor and a taxane, standard-of-care arm of a phase 3 trial
“The median overall survival among all 831 patients who had undergone randomization was 15.3 months in the 177Lu-PSMA-617 group, as compared with 11.3 months in the control group (hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001 [significance level, 0.05])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival by site of metastasis, docetaxel-treated trial participants
“Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with men with liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote